Clinical Trials on Platinum-resistant Recurrent Ovarian Cancer in New Zealand

Total 1240 results

ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Active, not recruiting

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Hepatocellular Carcinoma | Ovarian Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Microsatellite Instability-High

United States, Canada
Icahn School of Medicine at Mount Sinai

Completed

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Prostatic Neoplasms | Prostate Cancer | Prostate Neoplasms

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina
National Cancer Institute (NCI)

Active, not recruiting

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin

Testicular Germ Cell Tumor | Ovarian Cancer

United States
Genmab

Completed

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Melanoma | Sarcoma | Cervical Cancer | Ovarian Cancer | Endometrial Cancer | Solid Tumors | Thyroid Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, United Kingdom, Belgium, Denmark, Netherlands, Spain
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
Memorial Sloan Kettering Cancer Center
American Cancer Society, Inc.

Active, not recruiting

Determinants of Bladder Cancer Recurrence Study (The DETER Study)

Bladder Cancer

United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Kidney Cancer | Leukemia | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer | Melanoma (Skin)

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Completed

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Metastatic Castration-resistant Prostate Cancer

United States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
CellCentric Ltd.

Recruiting

Study to Evaluate CCS1477 in Advanced Tumours

Advanced Solid Tumors | Metastatic Breast Cancer | Non-small Cell Lung Cancer | Metastatic Castration-Resistant Prostate Cancer

United Kingdom, United States, Netherlands, France, Spain, Sweden
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Dana-Farber Cancer Institute

Completed

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Desmoid Tumor | Adult Malignant Fibrous Histiocytoma of Bone

United States
GOG Foundation
Novartis Pharmaceuticals

Active, not recruiting

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Advanced, Persistent, or Recurrent Endometrial Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Access to Genetic Testing in Underserved Patients With Cancer

Malignant Solid Neoplasm | Breast Carcinoma | Metastatic Prostate Carcinoma | Ovarian Carcinoma | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Pancreatic Exocrine Neoplasm | Stage IVB Prostate Cancer American Joint Committee on Cancer v8

United States
AstraZeneca

Completed

AZD8186 First Time In Patient Ascending Dose Study

Advanced Castrate-resistant Prostate Cancer CRPC | Squamous Non-Small Cell Lung Cancer sqNSCLC | Triple Negative Breast Cancer TNBC

Spain, Canada, United States, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer (LEVER)

Atypical Endometrial Hyperplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

United States
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, France, United States, Australia, Brazil, Germany, Taiwan, Denmark, China, Netherlands, Japan, Canada, Finland, Italy, Hungary, Portugal, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
University of Rochester

Recruiting

A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence

Prostate Cancer | HDR

United States
Elicio Therapeutics

Active, not recruiting

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

Colorectal Cancer | Ovarian Cancer | Cholangiocarcinoma | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Minimal Residual Disease | Gallbladder Carcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Melanoma (Skin) | Carcinoma of Unknown Primary

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Arcus Biosciences, Inc.

Recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25)

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Bladder Cancer | Advanced Cancer | Non-Small Cell Lung Cancer (NSCLC) | Advanced Malignancies | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Gastroesophageal-junction...

United States, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Mixed Adenocarcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage... and other conditions

United States
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Singapore, Australia, France, Germany, Italy, United Kingdom
Bayer

Active, not recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Spain, Korea, Republic of, United Kingdom, Australia, Hong Kong, Singapore, Taiwan, Lithuania, Russian Federation, Turkey, France, Israel, Czechia, Italy, Germany, Finland, Austria, Poland, Hungary
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Celldex Therapeutics

Completed

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | Marginal Zone B Cell Lymphoma) | Any T-cell Malignancy | Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma | Hormone-refractory Prostate Adenocarcinoma, Ovarian... and other conditions

United States
Famewave Ltd.
Bristol-Myers Squibb

Active, not recruiting

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Melanoma | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Adenocarcinoma | Papillary Thyroid Cancer

Spain, United States, Israel
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Recurrent Breast Carcinoma | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
VA Office of Research and Development

Recruiting

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA)

Metastatic Castrate Resistant Prostate Cancer | BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | RAD51B, RAD51C, RAD51D, or RAD54L Mutations

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Mucositis | Tongue Cancer | Oral Complications | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent... and other conditions

United States
Incyte Corporation

Terminated

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Nasopharyngeal Cancer | Esophageal Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Cholangiocarcinoma | Solid Tumors

United States, Belgium
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma | Acute Myeloid Leukemia | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Stage III Pancreatic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Chinese University of Hong Kong

Recruiting

A Novel Oral Synbiotic Formula in Reducing Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers

Colorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma

Hong Kong
National Cancer Institute (NCI)
GlaxoSmithKline

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Invasive Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
Prelude Therapeutics

Completed

A Study of PRT2527 in Participants With Advanced Solid Tumors

Sarcoma | Non-small Cell Lung Cancer | Castrate Resistant Prostate Cancer | Solid Tumors With Known MYC Amplification | Hormone Receptor Positive HER2 Negative Breast Cancer

United States
OncoC4, Inc.
National Cancer Institute (NCI)

Recruiting

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)

Cervical Cancer | Small Cell Lung Cancer | Adenoid Cystic Carcinoma | Metastatic Renal Cell Carcinoma | Metastatic Colorectal Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Melanoma | Pancreas Cancer | Metastatic... and other conditions

United States, Australia
Exact Sciences Corporation

Completed

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Kidney Cancer | Stomach Cancer | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Liver Cancer | Renal Pelvis Cancer | Uterine Cancer

United States

Clinical Trials on Platinum-resistant Recurrent Ovarian Cancer in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations